unknown
Stage
1
Investors
About
Chameleon Biosciences develops next-generation adeno-associated virus (AAV) vectors with reduced immune response to enable repeat dosing and enhanced efficacy for gene replacement and editing therapies targeting diseases such as hemophilia and Niemann-Pick Type C.
Explore Chameleon Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.